Poxvirus vectors: cytoplasmic expression of transferred genes.
During the past year there have been a number of advances in poxvirus vector design and application. These include improvements in gene expression and a direct method of inserting DNA into the poxvirus genome. Alternative methods of selecting recombinant viruses have been developed, and attenuated and non-replicating vaccinia virus and avian poxvirus vectors are now being used successfully. Field trials of an oral, wild-life rabies vaccine, and phase 1 testing of human vaccines derived from vaccinia virus are in progress. This review is an updated and modified version of a review first published in Current Opinion in Biotechnology 1992, 3:533-539.
Moss
B
B
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20292.
D000818:Animals; D001435:Bacteriophages / Q000235:genetics; D002645:Chickens; D015967:Gene Expression Regulation, Viral; D005822:Genetic Vectors; D006801:Humans; D008322:Mammals; D011212:Poxviridae / Q000145:classification / Q000235:genetics* / Q000502:physiology; D011401:Promoter Regions, Genetic; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis; D014611:Vaccination / Q000662:veterinary; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014616:Vaccinia virus / Q000235:genetics / Q000502:physiology; D014765:Viral Vaccines
D011993:Recombinant Fusion Proteins; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014765:Viral Vaccines